Kana Lessig Stemsoft Software May 2026

As the industry moves from bench to bedside, the bottleneck often isn't the science—it’s the documentation. The Challenge of Modern Cellular Therapies

(e.g., a case study or press release).

The field of cellular therapy is moving at breakneck speed. CAR-T, IEC, and other advanced therapy medicinal products (ATMPs) are revolutionizing patient care, transforming how we treat cancer and other diseases. Yet, with this incredible innovation comes a complex reality: managing the data of human cells as a raw material requires unprecedented precision. Kana Lessig Stemsoft Software

all of their CAR-T, IEC, and research work. Ensure compliance with 21 CFR Part 11, HIPAA, and GDPR.

STEMSOFT provides the industry's leading cellular therapy software solutions, designed specifically to manage this complexity. By offering comprehensive informatics solutions that focus on end-to-end information management, we empower providers to: As the industry moves from bench to bedside,

Data aggregation is only the first step. True success lies in data mining. STEMSOFT platforms, including StemLab™ and BMTserve™, allow laboratories to generate actionable insights and visualizations on the fly—without needing to be a report-writing expert.

(like StemLab or BMTserve).

Manufacturing and administering advanced therapies requires complete, accurate, and detailed records. Whether you are a cord blood bank, a public marrow transplant center, or a commercial cell therapy manufacturer, the regulatory landscape is constantly evolving, requiring strict adherence to FACT/JACIE, AABB, cGMP, and cGTP standards.